NCT05778071: An ongoing trial by Amolyt Pharma
This trial is ongoing. It must report results 2 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05778071 |
|---|---|
| Title | A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 7, 2023 |
| Completion date | Nov. 15, 2024 |
| Required reporting date | Nov. 15, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |